Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for bladder cancer patients who failed standard therapy

NCT ID NCT06351904

Recruiting now Disease control Sponsor: Ractigen Therapeutics. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times

Summary

This early-stage study tests a new drug called RAG-01 in about 72 adults with a type of bladder cancer (non-muscle-invasive) that did not get better with standard BCG therapy. The main goals are to check the drug's safety, find the best dose, and see if it helps control the cancer. Participants will receive RAG-01 and be closely monitored for side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GenesisCare North Shore

    RECRUITING

    St Leonards, New South Wales, 2065, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peninsula & South Eastern Haematology and Oncology Group

    RECRUITING

    Melbourne, Victoria, 3199, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Royal Melbourne Hospital

    RECRUITING

    Melbourne, Victoria, 3050, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)